{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:28:56Z","timestamp":1790724536830,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ijrobp.2023.08.044","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T02:10:21Z","timestamp":1692843021000},"page":"1531-1540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer"],"prefix":"10.1016","volume":"118","author":[{"given":"Jian","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo A.","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin S.","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Farach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Ying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Zsigmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuyong","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Mejia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Hsia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0829-2111","authenticated-orcid":false,"given":"Eric H.","family":"Bernicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.08.044_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0002","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label keynote-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0003","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0004","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0006","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab012","article-title":"Response rate and survival at key timepoints with PD-1 blockade versus chemotherapy in PD-l1 subgroups: Meta-analysis of metastatic NSCLC trials","volume":"5","author":"Man","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0007","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1158\/1078-0432.CCR-22-0602","article-title":"Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune checkpoint inhibitors and had ici-free intervals (wjog9616l)","volume":"15","author":"Akamatsu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/CCO.0000000000000802","article-title":"Recent advances in primary resistance mechanisms against immune checkpoint inhibitors","volume":"34","author":"Li","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0010","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1002\/cncr.33142","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials","volume":"126","author":"Borghaei","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0011","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0012","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1158\/2326-6066.CIR-13-0141","article-title":"Harnessing the potential of radiation-induced immune modulation for cancer therapy","volume":"1","author":"Ahmed","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0013","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0014","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0015","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-12-0210","article-title":"Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies","volume":"72","author":"Verbrugge","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: A randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0017","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy versus pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0018","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/10430349950018229","article-title":"In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial","volume":"10","author":"Herman","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0019","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1023\/B:NEON.0000003657.95085.56","article-title":"Adenovirus\/herpes simplex-thymidine kinase\/ganciclovir complex: Preliminary results of a phase 1 trial in patients with recurrent malignant gliomas","volume":"65","author":"Germano","year":"2003","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0020","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/sj.mt.6300096","article-title":"Suicide gene therapy with adenoviral delivery of HSV-TK gene for patients with local recurrence of prostate cancer after hormonal therapy","volume":"15","author":"Nasu","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0021","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0360-3016(01)01698-4","article-title":"Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model","volume":"51","author":"Vlachaki","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0022","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2011.35.5222","article-title":"Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma","volume":"29","author":"Chiocca","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0023","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0090-4295(99)00295-2","article-title":"Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer","volume":"54","author":"Atkinson","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0024","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.omtm.2022.07.001","article-title":"Efficacy of HSV-TK\/GCV system suicide gene therapy using SHED expressing modified HSV-TK against lung cancer brain metastases","volume":"26","author":"Oishi","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0025","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1073\/pnas.91.8.3054","article-title":"Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo","volume":"91","author":"Chen","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0026","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-22-0622","article-title":"A phase 2 trial of enhancing immune checkpoint blockade by stereotactic radiation and in situ virus gene therapy in metastatic triple-negative breast cancer","volume":"28","author":"Sun","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0027","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1470-2045(13)70274-2","article-title":"Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (aspect): A randomised, open-label, phase 3 trial","volume":"14","author":"Westphal","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034010","article-title":"Indirect comparison between immunotherapy alone and .immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: A systematic review","volume":"10","author":"Li","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0029","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/B:NEON.0000021897.53969.ca","article-title":"The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects","volume":"67","author":"Nestler","year":"2004","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0030","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0031","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-21-1171","article-title":"Baff attenuates immunosuppressive monocytes in the melanoma tumor microenvironment","volume":"82","author":"Liu","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0032","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004034","article-title":"Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders","volume":"10","author":"Zhou","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0034","doi-asserted-by":"crossref","first-page":"eabo5871","DOI":"10.1126\/sciadv.abo5871","article-title":"The evolving role of tissue-resident memory T cells in infections and cancer","volume":"8","author":"Yenyuwadee","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2020.10.028","article-title":"Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer","volume":"143","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2023.08.044_bib0036","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1158\/1078-0432.CCR-21-0697","article-title":"Role of B cells in responses to checkpoint blockade immunotherapy and overall survival of cancer patients","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623078367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623078367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:12:16Z","timestamp":1759745536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623078367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0360301623078367"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.08.044","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.08.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}